ENDEAR primary endpoint: event-free survival

ENDEAR

SPINRAZA® (nusinersen) increased event-free survival and overall survival in patients with infantile-onset (Type 1) spinal muscular atrophy (SMA).1

Primary endpoint: event-free survival1*

Chart showing a 47% reduction in risk of death with SPINRAZA
Chart showing a 47% reduction in risk of death with SPINRAZA

47%

reduction in risk of death or permanent ventilation (HR=0.53; P=0.005)1

  • Untreated
  • 41
  • 30
  • 14
  • 9
  • 7
  • 7
  • SPINRAZA
  • 80
  • 59
  • 46
  • 29
  • 16
  • 13

47%

reduction in risk of death or permanent ventilation (HR=0.53; P=0.005)1

*Event-free survival defined as time to death or permanent assisted ventilation (tracheostomy or ≥16 hours of ventilatory support per day for >21 continuous days in the absence of an acute reversible event).1

Patients treated with SPINRAZA had a 63% reduction in risk of death alone compared with untreated patients (84% SPINRAZA vs 61% untreated; HR=0.37; P=0.004).1

 

Review the warnings and precautions including thrombocytopenia, coagulation abnormalities, and renal toxicity

Cameron
age 2.5

Infantile-onset (Type 1) SMA
treated with SPINRAZA

Cameron
age 2.5

Infantile-onset (Type 1) SMA
treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.